For your patients with HR+, HER2-, early-stage, invasive breast cancer
The Oncotype DX Breast Recurrence Score® report provides three points of clarity to aid in treatment decisions as to whether adjuvant chemotherapy is needed or not for node-negative and node-positive (N1: up to 3 positive lymph nodes), hormone receptor-positive, HER2-negative, early-stage breast cancer patients.
Use our online Physician Portal
Order tests securely, access results quickly, sign documents, assign delegates, receive updates and more benefits available in one place.
3 pieces of information provided by the test
Recurrence Score® result
This number, between 0 and 100, is calculated by measuring the activity of specific genes in the breast cancer tissue. The Recurrence Score result is used to predict the risk of the breast cancer returning at a distant site and whether chemotherapy may help reduce the risk.1-5
Distant recurrence riska
This percentage indicates the risk that the breast cancer will come back somewhere else in the body, “distant recurrence,” within 10 years (node-negative)1,6 or 5 years (node-positive)4,9,10 when treated with hormonal therapy alone for 5 years.
Absolute chemotherapy benefita
This percentage indicates the benefit expected for the Recurrence Score group from adding chemotherapy to hormonal therapy in order to reduce the risk of cancer recurrence or death.2-4, 8-10
- These results are valid in HR+, HER2-, early-stage, invasive breast cancer patients treated with 5 years of endocrine therapy.
Explore the patient reports
Node-Negative
 |
Accounting for Age |
|
The report is stratified by age - ≤50 years and >50 years |
 |
Recurrence Score result |
|
The Recurrence Score result is based on the quantitative analysis of the expression of 21 genes within the patient’s tumour sample. This number, from 0 to 100, is used to determine distant recurrence risk at 10 years (prognosis) and absolute chemotherapy benefit (prediction). |
 |
Prognosis |
|
Your patient’s individualised 10-year distant recurrence risk (%) with endocrine therapy alone.* *Based on the |
 |
Prediction |
|
The absolute chemotherapy benefit (%) is based on the average benefit of chemotherapy in patients who had the same range of Recurrence Score results.* *Based on the |
 |
Single-Gene Scores |
|
Quantitative ER, PR, and HER2 scores by RT-PCR, specific to your patient.
|
 |
Clinical trial description |
|
Contains relevant study details from NSABP B-14, NSABP B-20 or TAILORx. For patients ≤50 years with Recurrence Score results 16-25 this section also contains information on chemotherapy benefit stratified by clinical risk
|
 |
Additional study information |
|
Displays the patient’s individualized Recurrence Score® result in the context of the relevant study data from either TAILORx trial or the NSABP B-20 trial. This example is for a patient over 50 years of age and shows the difference in the 10-year risk of distant recurrence when a patient with a Recurrence Score result of 15 is treated with chemotherapy and endocrine therapy vs endocrine therapy alone.
For all ages and Recurrence Score results 51-100, the data is only available for the group. Therefore the graph from NSABP B-20 Recurrence Score results 0-50 is shown for information only. |
 |
Data Details |
| Details regarding the data used to report distant recurrence risk and absolute chemotherapy benefit, including clinical trial characteristics, sample sizes, and confidence intervals. |
Node-Positive
|
Menopausal State |
|
Now includes the patient’s menopausal status |
|
Recurrence Score Result |
|
The Recurrence Score result is based on the quantitative analysis of the expression of 21 genes within the patient’s tumour sample. |
|
Prognosis |
|
Patient’s individualised risk of distant recurrence or individualised risk of recurrence or mortality when treated with endocrine therapy alone.*
*Based on the |
|
Prediction |
|
The Group Average Absolute Chemotherapy Benefit is the potential reduction in distant recurrence risk across all ages within this range of Recurrence Score® results when chemotherapy is added.*
*Based on the |
|
Confidence Interval Range |
|
The 95% confidence intervals provide the likely range of values for these measures. |
|
Single-Gene Scores |
|
Quantitative ER, PR, and HER2 scores by RT-PCR, specific to your patient. |
|
Study Details |
|
Contains relevant study details from either the |
|
Additional Study Information |
|
Displays the patient’s individualized Recurrence Score® result in the context of the relevant study data from either |
Further understanding the results
Node-negative patients
Patients with a Recurrence Score result of 0-25 generally do not benefit from the addition of chemotherapy to endocrine therapy.2,3,6,7
For patients under 50 years of age or yonger there is some chemotherapy benefit (in terms of DRFI) for those with Recurrence Score result:6,7
Patients with Recurrence Score results 26–100 have a significant and increasing benefit from the addition of chemotherapy to endocrine therapy.2,3
For patients under 50 years of age or yonger there is some chemotherapy benefit (in terms of DRFI) for those with Recurrence Score result:
- 16-20 and high clinical risk
- 21-25 regardless of clinical risk
Patients with Recurrence Score results 26–100 have a significant and increasing benefit from the addition of chemotherapy to endocrine therapy.
Node-positive patients
Post-menopausal patients with a Recurrence Score result of 0–25 do not benefit from the addition of chemotherapy to endocrine therapy.4,9,10
Pre-menopausal patients with Recurrence Score results of 0-25 have a 2.4% benefit (in terms of DRFI) from the addition of chemotherapy to endocrine therapy.9,10
All patients with Recurrence Score results 26-100 significantly benefit from the addition of chemotherapy to endocrine therapy.4
Pre-menopausal patients with Recurrence Score results of 0-25 have a 2.4% benefit (in terms of DRFI) from the addition of chemotherapy to endocrine therapy.
All patients with Recurrence Score results 26-100 significantly benefit from the addition of chemotherapy to endocrine therapy.
Abbreviations
CT, chemotherapy
ER, estrogen receptor
ET, endocrine therapy
HER2, human epidermal growth factor receptor 2
N1, node-positive
DRFI, Distance Recurrence-Free Interval
ER, estrogen receptor
ET, endocrine therapy
HER2, human epidermal growth factor receptor 2
N1, node-positive
DRFI, Distance Recurrence-Free Interval
References
- Paik et al. N Engl J Med. 2004.
- Paik et al. J Clin Oncol. 2006.
- Geyer et al. NPJ Breast Cancer. 2018.
- Albain et al. Lancet Oncol. 2010.
- Dowsett et al. J Clin Oncol. 2010.
- Sparano et al. N Engl J Med. 2018.
- Sparano et al NEJM Evidence 2024
- Exact Sciences. Data on file
- Kalinsky et al. NEJM. 2021.
- Kalinsky et al. SABCS 2021.
Get in touch
Have questions about Oncotype DX®?
